First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.-Reference-Cited by-同舟云学术

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:4099-4099
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Strosberg Jonathan R.¹,Wolin Edward M.²,Chasen Beth A.³,Kulke Matthew H.⁴,Bushnell David L⁵,Caplin Martyn E.⁶,Baum Richard P.⁷,Hobday Timothy J.⁸,Hendifar Andrew Eugene⁹,Lopera Sierra Maribel¹⁰,Oberg Kjell E.¹¹,Ruszniewski Philippe B.¹²,Krenning Eric¹³

Affiliation:

1. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;

2. Montefiore Einstein Center for Cancer Care, Bronx, NY;

3. Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;

4. Boston University/Boston Medical Center, Boston, MA;

5. University of Iowa, Iowa City, IA;

6. Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom;

7. Zentralklinik, Bad Berka, Germany, Bad Berka, Germany;

8. Mayo Clinic, Rochester, MN;

9. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA;

10. Advanced Accelerator Applications, New York, NY;

11. Uppsala University Hospital, Uppsala, Sweden;